Ternium Files 2024 Form 20-F
- 69
LUXEMBOURG, LU / ACCESS Newswire / March 28, 2025 / Ternium S.A. (NYSE:TX) announced that it has filed its annual report on Form 20-F, for the year ended December 31, 2024, with the U.S. Securities and Exchange Commission (SEC). The annual report can be downloaded from the SEC's website at www.sec.gov and from Ternium's website at www.ternium.com, in the Investors section.
Forward Looking Statements
Some of the statements contained in this press release are "forward-looking statements". Forward-looking statements are based on management's current views and assumptions and involve known and unknown risks that could cause actual results, performance or events to differ materially from those expressed or implied by those statements. These risks include but are not limited to risks arising from uncertainties as to gross domestic product, related market demand, global production capacity, tariffs, cyclicality in the industries that purchase steel products and other factors beyond Ternium's control.
About Ternium
Ternium is a leading steel producer in the Americas, providing advanced steel products to a wide range of manufacturing industries and the construction sector. We invest in low carbon emissions steelmaking technologies to support the energy transition and the mobility of the future. We also support the development of our communities, specially through educational programs in Latin America. More information about Ternium is available at www.ternium.com.
Contact Information
Sebastián Martí
Ternium - Investor Relations
+1 (866) 890 0443
+54 (11) 4018 8389
www.ternium.com
SOURCE: Ternium S.A.
View the original press release on ACCESS Newswire
ACCESSWIRE is a premier news and communications network, providing regional, national, and global news to hundreds of clients globally. In addition to our world class and ever growing distribution network, ACCESSWIRE is also leading the way in social engagement, targeting and analytics.
- BriaCell Announces Positive Recommendation from Data Safety Monitoring Board for Pivotal Phase 3 Study in Metastatic Breast Cancer
- Hardman & Co Research on Volta Finance Limited (VTAS): Volatility put into context
- Constellium Honored with Three Supplier Awards from Airbus
- Incannex Healthcare Expands Clinical Advisory Board to Support Obstructive Sleep Apnea Program with Appointment of Dr. Douglas B. Kirsch
- Plus Therapeutics Announces Comprehensive Restructuring of $15 Million March 2025 Equity Financing
- Abeona Therapeutics® Announces Publication in The Lancet of Phase 3 VIITAL™ Study Data in Recessive Dystrophic Epidermolysis Bullosa